| Revenue Growth | Revenue grew 11% to $38M; TRCV grew 9% to $154M. |
|---|---|
| Mgmt Confidence | High confidence in returning to growth and seeing clear multi-quarter progression. |
| Demand Visibility | Pipeline deals increased; TRCV of $154M provides strong recurring revenue visibility. |
| Order Book | Total recurring contract value (TRCV) reached $154 million, up 9% year-over-year. |
| Margin Trends | Adjusted EBITDA margin 28%; 4% headwind from HUB conference timing shift. |
| Op. Leverage | Revenue now absorbing delivery capacity investments; incremental dollars expected at additive margins. |
| Pricing Power | Strong retention; several longstanding customers moved to multi-year agreements. |
| Vol vs Price | Growth driven by large implementation and broad-based strength across portfolio segments. |
| Segment Growth | Market Insights strongest sales since pandemic; Governance Institute strongest in decade. |
| New Clients | Large multi-solution agreement went live; several new Market Insights logos added. |
| Capex & Debt | Paid $0.16 dividend; repurchased 790,000 shares; reduced capital expenditures. |
| Commentary | Focusing on moving from measuring experience to enabling frontline improvement actions. |
| New Launches | Piloting AI-enabled capabilities for data access and actionable insights. |
Growth
Revenue grew 11% to $38M; TRCV increased 9% to $154M year-over-year.
Outlook
Expect further sequential margin improvement in Q4 2026 and continued TRCV-to-revenue conversion.
Risks
Management used vague language regarding the specific revenue contribution timing for the 2027 rounding platform phase.
The company's earnings call, NASDAQ: NRC, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Nrc Health: key numbers
- Share price
- $26.33Close, Nov 16
- Market cap
- $559M
- Shares outstanding
- 21.22MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Commercial Physical & Biological ResearchSIC 8731
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Nrc Health
All →Nrc Health Q3 2026 Results: Net Income $4.7M, Up 14.1% YoY
NRC Health reported revenue of $38.4 million for the third quarter of 2026, an 11% increase over the prior year, though nine-month operating income fell from $17.9 million to $11.2 million due to higher selling, general, and administrative expenses. The company maintained its quarterly dividend of $0.16 per share while significantly increasing treasury stock repurchases, contributing to a total shareholders' deficit of $9.1 million.
- Key figure
- Net income $4.7M · +14.1% YoY
Nrc Health Financial Results
NRC Health reported third-quarter 2026 revenue of $38.4 million, an 11% increase year-over-year, driven by the successful launch of a large customer and multi-year renewals. The company also declared a quarterly cash dividend of $0.16 per share payable in January 2027.
- Term
- Q3 2026
“We delivered a strong third quarter, with revenue up 11% year-over-year and sequential margin expansion. Our large customer went live on schedule, and several long-standing customers renewed under multi-year agreements, reinforcing the durability of our recurring-revenue base. As our expanding contract base converts into revenue, the operating leverage inherent in our model will translate into greater profitability and free cash flow over time, reinforcing our confidence in NRC Health’s ability to create long-term shareholder value.”
Trent Green, CEO of NRC Health
Nrc Health Leadership Change
NRC Health has appointed its current CEO, Trent Green, to the additional role of interim principal financial officer effective October 14, 2026. No compensation changes were made in connection with this appointment, and Mr. Green has served as the company's CEO since June 2025.